Pancreatic Cancer Research

ResearcherUniversity of Wisconsin SystemActive in the last 2 years

Noelle K. LoConte

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3883-4153; OpenAlex author ID A5004212252, A5118176505. Sources: ClinicalTrials.gov.

Their work

Papers
21 (first author 1, last author 1)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
146
Papers, trials and grants by year

2008: 1 trial · 2009: none · 2010: none · 2011: none · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 2 papers · 2017: 2 papers · 2018: none · 2019: 3 papers · 2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 5 papers

Papers 21

  1. Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial. Co-author DOI 10.1038/s41591-026-04327-4↗
  2. Novel Electronic Health Record-Based Data Commons for Pancreatic Cancer. Co-author DOI 10.1200/cci-24-00265↗
  3. Association of Social Determinants of Health with Delays in Diagnosis and Treatment of Resected Pancreatic Ductal Adenocarcinoma (PDAC). Co-author DOI 10.1245/s10434-026-20419-4↗
  4. ASO Visual Abstract: Association of Social Determinants of Health with Delays in Diagnosis and Treatment of Resected Pancreatic Ductal Adenocarcinoma (PDAC). Co-author DOI 10.1245/s10434-026-20507-5↗
  5. Pancreatic Adenocarcinoma, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. Co-author DOI 10.6004/jnccn.2026.0046↗
  6. Immune-Based Therapies in Pancreatic Cancer: a Systematic Review of Ongoing Clinical Trials (2020-2022). Co-author DOI 10.1007/s12029-025-01194-z↗
  7. Neoadjuvant Stereotactic Body Radiation Therapy Plus Elective Nodal Irradiation With Concurrent Capecitabine for Patients With Resectable Pancreatic Cancer: Su… Co-author DOI 10.1016/j.prro.2025.01.011↗
  8. Association of Neighborhood Disadvantage with Short- and Long-Term Outcomes After Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-023-14347-w↗
  9. Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma. Co-author DOI 10.21037/jgo-22-946↗
  10. A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable … Co-author DOI 10.1097/sla.0000000000004669↗
  11. Treatment Inequity: Examining the Influence of Non-Hispanic Black Race and Ethnicity on Pancreatic Cancer Care and Survival in Wisconsin. Last author PMID 35857681↗
  12. A Phase 1 Dose Escalation Study of Neoadjuvant SBRT Plus Elective Nodal Radiation with Concurrent Capecitabine for Resectable Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2020.09.010↗
  13. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Co-author DOI 10.6004/jnccn.2021.0017↗
  14. A Phase I Study of Dinaciclib in Combination With MK-2206 in Patients With Advanced Pancreatic Cancer. Co-author DOI 10.1111/cts.12802↗
  15. A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer. Co-author DOI 10.1002/cam4.2425↗
  16. Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pa… Co-author DOI 10.1158/1078-0432.ccr-18-2992↗
  17. Pancreatic Adenocarcinoma, Version 1.2019. Co-author DOI 10.6004/jnccn.2019.0014↗
  18. Utilization of preoperative endoscopic ultrasound for pancreatic adenocarcinoma. Co-author DOI 10.1016/j.hpb.2017.01.017↗
  19. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Co-author DOI 10.6004/jnccn.2017.0131↗
  20. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Tri… Co-author DOI 10.1001/jamasurg.2016.1137↗
  21. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. First author DOI 10.1097/mpa.0000000000000458↗

Trials 1

  1. CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma Principal investigator NCT00634751↗

Closest collaborators

The 25 strongest of 146 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Syed Nabeel Zafar · 6 shared papers, 2022–2026 · strength 1.36
  2. Clayton Thomas Marcinak · 4 shared papers, 2024–2026 · strength 1.01
  3. Sharon Marie Weber · 5 shared papers, 2021–2026 · strength 0.88
  4. Muhammad Maisam Ali · 3 shared papers, 2026 · strength 0.83
  5. Benjamin A. Y. Cher · 2 shared papers, 2026 · strength 0.58
  6. Jeremy D. Kratz · 2 shared papers, 2025 · strength 0.51
  7. Andrew H. Ko · 6 shared papers, 2016–2026 · strength 0.50
  8. Daniel Erik Abbott · 3 shared papers, 2021–2025 · strength 0.49
  9. kaleem sohail Ahmed · 2 shared papers, 2024–2026 · strength 0.43
  10. Dana Backlund Cardin · 5 shared papers, 2016–2026 · strength 0.42
  11. Andrew M. Lowy · 5 shared papers, 2016–2026 · strength 0.42
  12. Andrea M. Schiefelbein · 2 shared papers, 2022–2026 · strength 0.40
  13. Brian G. Czito · 4 shared papers, 2017–2026 · strength 0.38
  14. Robert A. Wolff · 4 shared papers, 2017–2026 · strength 0.38
  15. Courtney L. Scaife · 4 shared papers, 2017–2026 · strength 0.38
  16. Eric K. Nakakura · 4 shared papers, 2017–2026 · strength 0.38
  17. Mokenge Peter Malafa · 4 shared papers, 2017–2026 · strength 0.38
  18. Jeffrey M. Hardacre · 4 shared papers, 2017–2026 · strength 0.38
  19. Brian Matthew Wolpin · 4 shared papers, 2017–2026 · strength 0.38
  20. Mary E. Dillhoff · 4 shared papers, 2017–2026 · strength 0.38
  21. Vincent M. Chung · 4 shared papers, 2017–2026 · strength 0.38
  22. Al B. Benson · 4 shared papers, 2017–2026 · strength 0.38
  23. Elena Gabriela Chiorean · 4 shared papers, 2017–2026 · strength 0.38
  24. Christos K Fountzilas · 3 shared papers, 2019–2026 · strength 0.33
  25. Amol Kumar Narang · 3 shared papers, 2019–2026 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.